Form 4: Generation Bio Director Disposes Shares Post-Merger

Generation Bio Co. Director Geoff McDonough reports the disposition of all common stock and cancellation of stock options following the company's merger with XOMA Royalty Corporation's subsidiary.

Summary

• Generation Bio Co. (the "Issuer") completed a merger with XRA 7 Corp. ("Merger Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation ("Parent"), effective February 9, 2026.
• Common stock shares were exchanged for a purchase price of $4.2913 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• The CVR represents the right to receive certain contingent payments in cash, with an estimated maximum contingent consideration amount of $25.01 per CVR.
• Geoff McDonough, a director of Generation Bio Co., disposed of 138,492 shares of common stock held directly.
• Additionally, 22,646 shares held indirectly by the McDonough Family 2018 Irrevocable Trust and 27,500 shares held indirectly by the McDonough Family 2020 Irrevocable Trust were disposed of.
• All outstanding and unexercised stock options with an exercise price per share equal to or greater than the cash amount ($4.2913) were automatically cancelled for no consideration immediately prior to the merger's effective time.
• Cancelled stock options included those with exercise prices ranging from $9.255 to $302.5, totaling 264,213 underlying shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a factual report of a director's beneficial ownership changes due to a completed merger, with no inherent positive or negative operational news for the surviving entity.

Positives

• Shareholders received a cash payment of $4.2913 per share as part of the merger consideration.
• The contingent value right (CVR) offers potential future cash payments, with an estimated maximum contingent consideration of $25.01 per CVR, providing potential upside beyond the initial cash.

Negatives

• Stock options with an exercise price equal to or greater than the cash amount ($4.2913) were cancelled for no consideration, resulting in a loss of potential value for option holders.
• The contingent value rights (CVRs) are non-tradeable, limiting liquidity and immediate monetization for recipients.

Risks

• The value of the contingent value rights (CVRs) is not guaranteed and depends on future events and conditions as per the contingent value rights agreement.
• The CVRs are non-tradeable, meaning holders cannot sell them on an open market, which limits their liquidity and ability to realize value until contingent payments, if any, are made.

Future Outlook

The contingent value rights (CVRs) provide a mechanism for Generation Bio Co. stockholders to potentially receive future cash payments, contingent upon specific events and conditions outlined in the CVR agreement.

Industry Context

StockSavvy.ai notes that the use of Contingent Value Rights (CVRs) in mergers, particularly in the biotechnology and pharmaceutical sectors, is a common strategy to bridge valuation gaps between an acquirer and target company. CVRs allow for additional payments to target shareholders if certain milestones (e.g., clinical trial success, regulatory approval, sales targets) are met post-acquisition, aligning incentives and providing potential upside for contingent future events.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of shares through the McDonough Family 2018 Irrevocable Trust and the McDonough Family 2020 Irrevocable Trust, where the reporting person is the settlor, constitutes related party dealings.

Stakeholder Impact

• Shareholders of Generation Bio Co. received a combination of cash and contingent value rights (CVRs) for their shares.
• Employees holding stock options with exercise prices at or above the cash merger consideration had their options cancelled for no value.

Next Steps

• The terms and conditions of the contingent value rights agreement will dictate any future contingent payments to CVR holders.

Key Dates

Keywords

Generation Bio, GBIO, XOMA Royalty Corporation, Merger, Contingent Value Right, CVR, Stock Options, Beneficial Ownership, Insider Transaction, Corporate Acquisition